Literature DB >> 23108375

SOCS-3 is downregulated in progressive CKD patients and regulates proliferation in human renal proximal tubule cells in a STAT1/3 independent manner.

Hannes Neuwirt1, Iris E Eder, Martin Puhr, Michael Rudnicki.   

Abstract

Proliferation and the sequence of epithelial to mesenchymal transition (EMT) and mesenchymal to epithelial transition (MET), called epithelial-mesenchymal-epithelial (EME) cycling are pivotal mechanisms of kidney repair and fibrosis. Furthermore, data suggest that dedifferentiation (EMT) is a prerequisite for proliferation of tubule cells. These processes have been shown to be regulated by STAT1/3 signaling. Suppressor of cytokine signaling-3 (SOCS-3) is a negative regulator of STAT1/3 signaling. Using a transcriptomics data set of patients with proteinuric kidney diseases we found that low levels of SOCS-3 RNA were associated with high-serum creatinine values in the long-term follow-up, which suggested a role of SOCS-3, regulated signaling in progression of chronic kidney disease. This result was validated in an independent cohort of patients with proteinuric nephropathies on protein level. In addition ∼60% of STAT target genes were differentially expressed in relation to stable kidney disease patients. Using two renal cellular models and SOCS-3 knockdown by short interfering RNA we investigated SOCS-3 effects on oncostatin M-induced STAT activation, differentiation and proliferation. SOCS-3 knockdown resulted in enhanced pSTAT1/3 phosphorylation and epithelial differentiation. The latter effect was only slightly enhanced by OSM treatment. Cellular proliferation was inhibited after SOCS-3 knockdown. This effect could not be further stimulated by OSM. Effects of SOCS-3 knockdown were not enhanced by downregulation of STAT1/3, suggesting a STAT independent effect on cell cycle regulators. Indeed, knockdown and overexpression of SOCS-3 were associated with decrease and increase of cyclin D1, -E and proliferation, respectively. In summary, SOCS-3 inhibits phosphorylation of pSTAT1/3 in renal tubule cells. Additionally, we show for the first time that-in vivo-loss of SOCS-3 is associated with unfavorable prognosis. In vitro, downregulation of SOCS-3 inhibits dedifferentiation (EMT) and cellular proliferation in kidney proximal tubule cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23108375     DOI: 10.1038/labinvest.2012.154

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  6 in total

1.  Suppressor of Cytokine Signaling-1 Peptidomimetic Limits Progression of Diabetic Nephropathy.

Authors:  Carlota Recio; Iolanda Lazaro; Ainhoa Oguiza; Laura Lopez-Sanz; Susana Bernal; Julia Blanco; Jesus Egido; Carmen Gomez-Guerrero
Journal:  J Am Soc Nephrol       Date:  2016-09-08       Impact factor: 10.121

2.  Expression of the anti-inflammatory suppressor of cytokine signaling 3 (SOCS3) in human clear cell renal cell carcinoma.

Authors:  Anja Urbschat; Svenja Stumpf; Jörg Hänze; Patrick Paulus; Thorsten J Maier; Christine Weipert; Rainer Hofmann; Axel Hegele
Journal:  Tumour Biol       Date:  2016-01-22

3.  Pattern-recognition receptor signaling regulator mRNA expression in humans and mice, and in transient inflammation or progressive fibrosis.

Authors:  Roman Günthner; Vankayala Ramaiah Santhosh Kumar; Georg Lorenz; Hans-Joachim Anders; Maciej Lech
Journal:  Int J Mol Sci       Date:  2013-09-04       Impact factor: 5.923

4.  miR-885-5p upregulation promotes colorectal cancer cell proliferation and migration by targeting suppressor of cytokine signaling.

Authors:  Meng Su; Baoli Qin; Fang Liu; Yuze Chen; Rui Zhang
Journal:  Oncol Lett       Date:  2018-05-07       Impact factor: 2.967

5.  Reduced eIF3d accelerates HIV disease progression by attenuating CD8+ T cell function.

Authors:  Ying Pan; Zi-Ning Zhang; Lin-Bo Yin; Ya-Jing Fu; Yong-Jun Jiang; Hong Shang
Journal:  J Transl Med       Date:  2019-05-22       Impact factor: 5.531

6.  Induction of SOCS Expression by EV71 Infection Promotes EV71 Replication.

Authors:  Wenying Gao; Min Hou; Xin Liu; Zhaolong Li; Yongjun Yang; Wenyan Zhang
Journal:  Biomed Res Int       Date:  2020-02-19       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.